Company profile: Fusion Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
Products and services
- Targeted Alpha Therapeutics: Architects clinical-stage therapies harnessing alpha-emitting isotopes to precisely target and kill cancer cells, building radiopharmaceutical products focused on high-precision oncologic targeting
- Fast-Clear™ Linker Technology: Proprietary linker component engineered to improve radiopharmaceutical safety by enhancing drug clearance from healthy tissue, decreasing exposure to non-target cells and supporting cleaner therapeutic profiles
- FPI-2265: Phase 2 radiopharmaceutical targeting PSMA in prostate cancers, constructed to bind PSMA-expressing tumors for therapeutic effect
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fusion Pharmaceuticals
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
Dragonfly Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies harnessing the innate and adaptive immune systems. Offers the TriNKET platform for tri-specific immune engagers and a CYTOKINE platform for cytokine-based therapies for cancer and other diseases. Pipeline includes DF1001 (HER2, solid tumors), DF9001 (EGFR, solid tumors), DF6215 (IL-2, advanced solid tumors), and DF6002 (IL-12, extended half-life) for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dragonfly Therapeutics company profile →
Piramed
HQ: United Kingdom
Website
- Description: Provider of inhibitor-focused drug discovery and development of new medicines targeting cancer and immune inflammatory disorders, with applications across cardiovascular disease and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Piramed company profile →
Aptevo Therapeutics
HQ: United States
Website
- Description: Provider of bispecific immunotherapies and platform technologies for cancer treatment, focused on oncology and hematology. Portfolio includes ADAPTIR and ADAPTIR-FLEX platforms, plus candidates APVO436 (CD3xCD123, Phase 2 AML), APVO603 (4-1BB/OX40), APVO442 (PSMA/CD3 for prostate cancer), and APVO711 (PD-L1/CD40).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptevo Therapeutics company profile →
Five Prime Therapeutics
HQ: United States
Website
- Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Five Prime Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fusion Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fusion Pharmaceuticals
2.2 - Growth funds investing in similar companies to Fusion Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fusion Pharmaceuticals
4.2 - Public trading comparable groups for Fusion Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →